Article Information
- Received July 20, 2014
- Revision received November 9, 2014
- Accepted December 6, 2014
- First published January 28, 2015.
- Version of record published January 28, 2015.
Author Information
Author contributions
Author contributions: T.G., E.H.B., S.W., E.R., M.-M.M., and C.G. designed research; T.G., M.P., S.T.P., A.M., K.W., S.W., E.R., M.-M.M., and C.G. performed research; E.H.B., S.W., E.R., M.-M.M., and C.G. contributed unpublished reagents/analytic tools; T.G., M.P., A.R., S.W., E.R., M.-M.M., and C.G. analyzed data; T.G., S.W., E.R., M.-M.M., and C.G. wrote the paper.
Disclosures
- Received July 20, 2014.
- Revision received November 9, 2014.
- Accepted December 6, 2014.
This project was supported by a grant from the National Institute on Aging, National Institutes of Health (NIH Grant AG045571), The Davee Foundation, the Northwestern University Alzheimer's Disease Core Center grant from the National Institute on Aging (Grant AG13854), an NRSA fellowship from the National Institute on Aging (Grant F31-AG043270), the American Psychological Foundation (Grant 5UL1RR025741 now at the National Center for Advancing Translational Sciences Grant 8UL1TR000150), and an Early Investigator Grant from the Alzheimer's Disease Research Fund, Illinois Department of Public Health. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI; NIH Grant U01 AG024904) and Department of Defense ADNI (Grant W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec; Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche and its affiliated company Genentech; GE Healthcare; Innogenetics; IXICO; Janssen Alzheimer Immunotherapy Research and Development; Johnson and Johnson Pharmaceutical Research and Development; Medpace; Merck; Meso Scale Diagnostics; NeuroRx Research; Novartis Pharmaceuticals; Pfizer; Piramal Imaging; Servier; Synarc; and Takeda Pharmaceutical. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California.
The authors declare no competing financial interests.
Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
- Correspondence should be addressed to Tamar Gefen, M.S., Northwestern University, Cognitive Neurology and Alzheimer's Disease Center (CNADC), 320 E. Superior Street, Searle Building 11th Floor, Chicago, IL 60611. tamar.gefen5{at}gmail.com
Online Impact
